Maridebart cafraglutide
Fat LossInvestigational GIP antagonist / GLP-1 agonist antibody-peptideEmerging
Amgen bispecific molecule (GIPR antagonist + GLP-1R agonist) in Phase 2/3 obesity development. Monthly-class PK in trials. Not FDA-approved.
For research use only.
Key Facts
- CAS
- 2760218-55-9
- Molecular Weight (MW)
- ≈145–154 kDa (conjugate; assay-dependent)
- Half-life
- Long (monthly or less frequent dosing in trials)
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- Monthly or less frequent (per study arm)
- Last updated
- 8/23/2026
- Targets
- GIP receptorGLP-1 receptor
Overview
Amgen bispecific molecule (GIPR antagonist + GLP-1R agonist) in Phase 2/3 obesity development. Monthly-class PK in trials. Not FDA-approved.
Protocol
- Dosage Range
- Per trial protocol
- Frequency
- Monthly or less frequent (per study arm)
- Cycle
- Per study
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
Science
Mechanism of Action
Antibody-peptide conjugate that blocks GIP receptor while activating GLP-1 receptor, aiming for large weight loss with infrequent dosing.
Targets
GIP receptorGLP-1 receptor
Studies
- AMG 133 / maridebart cafraglutide obesity study— Journal/year not available
Benefits
Investigational obesity candidateInfrequent-dosing research
Potential Side Effects
- GI effects
- Antibody-related reactions possible
References
- PMID 38378051External link · Year —